BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Collagenase Clostridium Histolyticum

Corporal Rupture [Penile Fracture] or Other Serious Penile Injury in the Treatment of Peyronie's Disease

  • Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies. In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile “popping” sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded. Severe penile hematoma was also reported as an adverse reaction in 39 of 1044 (3.7%) XIAFLEX-treated patients [see Warnings and Precautions (5.2)].
  • Signs or symptoms that may reflect serious penile injury should be promptly evaluated to assess for corporal rupture or severe penile hematoma which may require surgical intervention [see Warnings and Precautions (5.2)].
  • Because of the risks of corporal rupture or other serious penile injury, XIAFLEX is available for the treatment of Peyronie’s disease only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XIAFLEX REMS Program [see Warnings and Precautions (5.3)].

Approved Risk Evaluation and Mitigation Strategies (REMS)

XIAFLEX (Collagenase Clostridium Histolyticum) Injection

Patient Counseling Information

Medication Guides

Patient Medication Guide

Package Inserts

Collagenase Clostridium Histolyticum

Collagenase Colstridium Histolyticum-aaes

Additional Information

PubMed - XIAFLEX

Updated January 2018